No CrossRef data available.
Article contents
Toxicity of lofepramine and fluvoxamine in heart disease
Published online by Cambridge University Press: 13 June 2014
Abstract
Therapeutic doses of lofepramine and fluvoxamine were associated with the development of first degree and second degree heart block, respectively, in an 83 year old man with a normal ECG prior to treatment and with no history of cardiovascular disease. Caution is recommended in treating patients with newer generation antidepressants, even in cases where cardiac status appears normal prior to treatment.
Keywords
- Type
- Brief Reports
- Information
- Copyright
- Copyright © Cambridge University Press 1994
References
1.Gerson, SC, Plotkin, DA, Jarvik, LF. Antidepressant drug studies 1964 to 1986: empirical evidence fore ageing patients. J Clin Pharmacol 1988; 8:311–22Google Scholar
2.Foltyn, P. The treatment of depressive conditions in elderly patient. Arztliche Praxis 1979; 96:3963.Google Scholar
3.Gokelma, Y. Heart effects of lofepramine in depressed patients with or without heart disease. 1983. Presented at the VII World Congress of Psychiatry, Vienna.Google Scholar
4.Roos, JC. Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine. Br J Clin Pharmacol 1983; 15:439s–45s.CrossRefGoogle ScholarPubMed
5.Prager, , et al. Cardiotropic effects of antidepressants:a comparison with fluvoxamine. Adv Pharmacother 1986; 2:133–50.Google Scholar
6.American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed (revised). Washington DC: American Psychiatric Association, 1987.Google Scholar
7.Robinson, JF, Doogan, DP. A placebo controlled study of the cardiovascular effects of fluvoxamine and clovoxamine in human volunteers. British Journal of Clin Pharmacol 1982; 14:805–8.CrossRefGoogle ScholarPubMed
8.Johnson, BA, McCann, J. Toxicity of lofepramine in heart disease. Ir J Psychol Med 1990;7:142–3.CrossRefGoogle Scholar